List of Excipients in Branded Drug LOFEXIDINE HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Prasco Laboratories	LOFEXIDINE HYDROCHLORIDE	lofexidine hydrochloride	66993-345	CALCIUM STEARATE
Prasco Laboratories	LOFEXIDINE HYDROCHLORIDE	lofexidine hydrochloride	66993-345	CELLULOSE, MICROCRYSTALLINE
Prasco Laboratories	LOFEXIDINE HYDROCHLORIDE	lofexidine hydrochloride	66993-345	CITRIC ACID MONOHYDRATE
Prasco Laboratories	LOFEXIDINE HYDROCHLORIDE	lofexidine hydrochloride	66993-345	LACTOSE

Generic Drugs Containing LOFEXIDINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Novadoz Pharmaceuticals LLC	lofexidine hydrochloride	72205-246	ANHYDROUS CITRIC ACID
Novadoz Pharmaceuticals LLC	lofexidine hydrochloride	72205-246	ANHYDROUS LACTOSE
Novadoz Pharmaceuticals LLC	lofexidine hydrochloride	72205-246	CALCIUM STEARATE
Novadoz Pharmaceuticals LLC	lofexidine hydrochloride	72205-246	FD&C BLUE NO. 2

What are the Most Frequently-Used Excipients in LOFEXIDINE HYDROCHLORIDE?

# Of NDCs	Excipient
1	ANHYDROUS CITRIC ACID
1	ANHYDROUS LACTOSE
1	CALCIUM STEARATE
1	FD&C BLUE NO. 2

Lofexidine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Lofexidine hydrochloride is a low-dose, immediate-release oral product with a narrow content-uniformity target, repeated daily dosing, and clinically important cardiovascular warnings. The strongest excipient opportunities are in low-dose direct-compression systems, granulation platforms, stability improvement, film coating, and cost-reduced generic manufacturing. The leading commercial threat is substitution by generic lofexidine tablets rather than biosimilar competition.

What is lofexidine hydrochloride used for?

Lofexidine hydrochloride is an oral alpha-2 adrenergic agonist approved by the U.S. Food and Drug Administration for mitigation of opioid withdrawal symptoms in adults. The marketed product, Lucemyra, contains 0.18 mg lofexidine per tablet and is administered multiple times daily for up to 14 days in the FDA-approved regimen.[1]

Attribute	Product profile
Active ingredient	Lofexidine hydrochloride
Pharmacologic class	Central alpha-2 adrenergic agonist
FDA indication	Mitigation of opioid withdrawal symptoms
Dosage form	Immediate-release tablet
Strength	0.18 mg per tablet
Standard dosing	Four tablets daily initially, with titration and a maximum of 0.72 mg per dose day depending on treatment phase
Treatment duration	Up to 14 days
Key safety issues	Hypotension, bradycardia, syncope, QT prolongation, rebound hypertension
Reference product	Lucemyra
Biosimilar relevance	None; this is a small-molecule drug
Generic pathway	ANDA, subject to reference-product and regulatory requirements

The product’s low active load is central to formulation design. A 0.18 mg dose requires uniform distribution of a small quantity of active pharmaceutical ingredient across a substantially larger tablet mass. Excipient selection therefore affects blend homogeneity, segregation, tablet weight variation, dissolution, and manufacturing yield.

What excipients are used in lofexidine hydrochloride tablets?

The Lucemyra prescribing information identifies a conventional immediate-release tablet system using common pharmaceutical excipients. The listed inactive ingredients include lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, and film-coating components.[1]

Reference-product excipient functions

Excipient category	Likely function in the tablet	Commercial relevance
Lactose monohydrate	Diluent and compressibility aid	Cost-effective bulk excipient; potential replacement target for lactose-free products
Microcrystalline cellulose	Diluent, dry binder, and compression aid	Supports direct compression and tablet mechanical strength
Croscarmellose sodium	Superdisintegrant	Supports rapid tablet breakup and immediate release
Colloidal silicon dioxide	Glidant and moisture-control aid	Improves powder flow and reduces manufacturing variability
Magnesium stearate	Lubricant	Controls ejection force but can impair wetting and dissolution if over-lubricated
Film-coating materials	Appearance, handling, identification, and swallowability	Opportunity for lower-cost, titanium-dioxide-free, or moisture-resistant coating systems

The excipient system is not technically complex in the way that an extended-release matrix, lipid formulation, or biologic delivery system would be. Its difficulty comes from dose uniformity and process control. A generic developer can use different inactive ingredients, but the substitution must preserve pharmaceutical equivalence, tablet performance, stability, and tolerability.

How should a generic manufacturer formulate lofexidine hydrochloride?

The preferred first-line platform is a low-dose immediate-release tablet made by direct compression or dry granulation. Wet granulation can be considered where the active or excipient blend has inadequate flow, but it adds water exposure, drying controls, and process complexity.

Direct-compression strategy

A direct-compression formulation can combine:

• A high-functionality filler-binder such as microcrystalline cellulose, spray-dried lactose, mannitol, or a co-processed excipient.
• A superdisintegrant such as croscarmellose sodium, crospovidone, or sodium starch glycolate.
• Colloidal silicon dioxide or another flow enhancer.
• A low-concentration lubricant, typically magnesium stearate or an alternative with a lower dissolution penalty.
• A protective film coat.

The principal development objective is content uniformity, not simply tablet hardness. A low-dose active can segregate from larger or denser excipient particles during transfer, hopper storage, and tableting. Particle-size matching, ordered mixing, geometric dilution, and controlled transfer distances can reduce that risk.

Dry-granulation strategy

Roller compaction can improve flow and reduce segregation when the active-excipient blend is poorly compressible. It also avoids aqueous exposure. The main risks are over-compaction, reduced tabletability after milling, and slower disintegration caused by overly dense granules.

Dry granulation is commercially attractive for high-volume generic production because it can reduce drying time and simplify scale-up. Its value is greatest when it improves yield or enables existing generic manufacturing equipment to produce the product without major capital expenditure.

Wet-granulation strategy

Wet granulation may improve uniformity where the active has poor flow or where a liquid binder creates stronger granules. It is less attractive for a first generic product when the formulation can meet specifications through direct compression or roller compaction.

Wet processing creates additional controls for:

• Water exposure and chemical stability.
• Drying endpoint.
• Residual moisture.
• Granule size distribution.
• Dissolution after scale-up.
• Potential interaction between the hydrochloride salt and binder system.

What formulation patents could protect lofexidine products?

Lofexidine has limited formulation complexity, so the most defensible intellectual-property opportunities are likely to involve specific manufacturing or performance advantages rather than broad excipient combinations.

Potential formulation claim areas

A developer could pursue claims directed to:

1. A low-dose tablet with defined content-uniformity limits.
2. A specific particle-size distribution for lofexidine hydrochloride.
3. A co-processed excipient system that reduces segregation.
4. A dry-granulated composition with defined disintegration and dissolution performance.
5. A moisture-protective film coat or packaging configuration.
6. A formulation that reduces food-effect variability.
7. An orally disintegrating or rapidly dispersing dosage form.
8. A fixed-dose product combining lofexidine with another treatment component.

Broad claims covering lactose, microcrystalline cellulose, croscarmellose sodium, silicon dioxide, and magnesium stearate would face substantial validity and obviousness pressure because those excipients are standard pharmaceutical tools. Patent strength would improve if the applicant could demonstrate an unexpected technical effect, such as materially better content uniformity, reduced degradation, improved dissolution after prolonged storage, or a clinically meaningful reduction in dosing burden.

Manufacturing-IP barriers

Manufacturing patents may have greater practical value than composition patents when the product has a narrow active-dose window. Relevant claim strategies include:

• Blend-order controls.
• Pre-blending of the active with a fine-particle carrier.
• Segregation-resistant granules.
• Roller-compaction force ranges.
• Lubrication time limits.
• Tablet compression-force windows.
• Packaging configurations that preserve stability in high humidity.

These claims can create a barrier for competitors even when the underlying excipients are widely available. Their commercial value depends on whether an alternative process can produce bioequivalent tablets at acceptable cost.

What is the FDA regulatory pathway for lofexidine generic products?

A conventional generic lofexidine tablet would normally proceed through an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence to the reference product and bioequivalence under FDA requirements.[2]

Key regulatory considerations include:

Regulatory issue	Implication for lofexidine
Same strength	The generic should match the 0.18 mg tablet strength unless a different pathway is justified
Same dosage form	Immediate-release tablet equivalence is central
Inactive ingredients	Differences are permitted if they do not affect safety, performance, or bioequivalence
Dissolution	Rapid and reproducible dissolution is important for an immediate-release product
Content uniformity	A major risk because of the low active load
Labeling	Safety warnings and dosing instructions must be consistent with the reference product
Waiver potential	Dose proportionality or BCS-related approaches may apply only if FDA criteria are met
Commercial scale-up	Process controls must maintain uniformity through validation batches

The FDA Inactive Ingredient Database can support excipient selection by showing prior use of specific excipients, routes, dosage forms, and maximum potency levels.[3] A formulation using established excipients generally has a lower regulatory burden than one using a novel excipient or an unusually high excipient load.

When does lofexidine lose exclusivity and what is the Orange Book status?

Lofexidine is a small molecule, so the principal exclusivity risk comes from generic ANDA filings and patent listings rather than biosimilars. FDA approval records identify Lucemyra under NDA 209229.[4] Orange Book patent and exclusivity data should be assessed at the specific product and listing level because patent listings, pediatric extensions, delistings, and litigation certifications can change over time.[5]

The commercial analysis should separate three timelines:

1. FDA regulatory exclusivity.
2. Listed-patent protection.
3. Actual commercial availability of an approved generic.

A patent may remain listed after regulatory exclusivity ends. Conversely, an approved generic may face a delayed launch because of a Paragraph IV dispute, settlement agreement, litigation stay, or business decision by the ANDA sponsor.

Paragraph IV challenge exposure

A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed. For lofexidine, the practical challenge targets could include:

• The approved use for opioid withdrawal.
• Dose and titration regimens.
• Formulation or tablet-composition claims.
• Manufacturing claims.
• Any patent listed for the reference product in the Orange Book.

The first applicant to submit a qualifying Paragraph IV certification may obtain 180-day generic exclusivity under the applicable statutory framework. The commercial value of that position depends on whether the patent estate can delay launch and whether other ANDA applicants are eligible to enter after the first filer’s exclusivity period.

Which companies are positioned to compete in lofexidine?

The competitive field includes the reference-product rights holder, generic pharmaceutical companies, contract manufacturers, excipient suppliers, and companies selling adjacent opioid-withdrawal products.

Direct competitors

The most relevant direct competitors are:

• Lucemyra, the branded lofexidine product.
• FDA-approved generic lofexidine tablets.
• Potential future ANDA products using alternative excipient systems.

The product competes clinically with non-lofexidine approaches used to manage withdrawal symptoms, including clonidine and symptom-specific supportive medicines. These alternatives can limit pricing power even if lofexidine retains advantages in label specificity or clinical positioning.

Excipient and CDMO opportunities

Commercial opportunities exist for suppliers that can offer:

• Low-dose blend uniformity expertise.
• Co-processed filler-binder systems.
• High-performance superdisintegrants.
• Low-magnesium-stearate lubrication systems.
• Moisture-resistant coating technology.
• Unit-dose or high-barrier packaging.
• Validated scale-up and analytical support.

A supplier with a qualified excipient platform can sell into multiple low-dose generic products, making the opportunity broader than lofexidine alone. The most valuable proposition is process performance, not merely replacement of one commodity excipient with another.

What are the strongest commercial opportunities in lofexidine excipients?

1. Lactose-replacement formulations

A lactose-free formulation can address procurement preferences, allergen policies, and manufacturing-site standardization. Mannitol, microcrystalline cellulose, dibasic calcium phosphate, and co-processed systems are possible alternatives. The formulation must maintain density, flow, compressibility, and dissolution.

2. Co-processed excipients for content uniformity

A co-processed filler-binder can improve powder flow and reduce active segregation. The strongest commercial case exists where the system reduces blend testing failures, tablet rejects, or scale-up risk.

3. Rapid-disintegration platforms

A faster-disintegrating tablet may improve product differentiation, though the clinical value is limited if the reference product already dissolves rapidly and the indication does not require rapid onset. A rapidly dispersing formulation could support a 505(b)(2) strategy, but it would likely require a stronger clinical and regulatory justification than a conventional ANDA.

4. Moisture-control systems

High-barrier blister packaging, desiccant-enabled bottles, and moisture-resistant film coatings can reduce degradation and extend shelf-life. Packaging is especially relevant when a formulation uses hygroscopic excipients or when stability results are sensitive to humidity.

5. Low-cost manufacturing platforms

A generic sponsor can improve margins by using the simplest process that meets content-uniformity and dissolution requirements. Direct compression is commercially attractive because it minimizes equipment, labor, and processing time. A proprietary process that reduces manufacturing cost without changing the dosage form can support a stronger supply or licensing position.

6. Combination and adherence products

Lofexidine is dosed several times daily, creating an opportunity for adherence-oriented packaging, calendar blister packs, and treatment-duration packs. A fixed-dose combination would be more difficult because it could alter regulatory classification, pharmacokinetics, and clinical positioning.

How strong is the patent estate for lofexidine formulations?

The patent estate should be viewed as stronger around therapeutic use and product-specific protection than around standard excipient combinations. Conventional immediate-release formulations are vulnerable to design-around unless the patent claims include a demonstrated technical effect.

IP category	Relative strength	Commercial assessment
Active-ingredient composition of matter	Low for a mature product	Usually expired or not available as a new-product barrier
Method of use	Moderate	Can delay substitution if listed and enforceable
Tablet composition	Low to moderate	Depends on narrow claim language and evidence of unexpected results
Manufacturing process	Moderate	Can protect a cost-efficient route if alternatives are difficult
Packaging and stability	Moderate	Useful where humidity or shelf-life is a demonstrated problem
Novel dosage form	Moderate to high	Stronger if it creates a differentiated pharmacokinetic or adherence profile
Excipient-only claims	Low	Common excipients create prior-art and obviousness challenges

Patent strength should be assessed claim by claim. The presence of an Orange Book listing does not establish validity, infringement, or commercial enforceability.

What litigation and settlement issues affect generic lofexidine entry?

Lofexidine litigation risk is concentrated in ANDA litigation under the Hatch-Waxman framework. Relevant events include:

• A Paragraph IV notice letter.
• Filing of a patent-infringement action within 45 days.
• A potential 30-month stay of FDA approval.
• Settlement terms governing launch timing.
• Authorized-generic arrangements.
• Covenants not to sue or license agreements.
• At-risk launch decisions.

Settlement agreements can materially change the commercial entry date without invalidating the listed patent. The most important diligence items are the agreed launch date, any acceleration triggers, restrictions on supply, authorized-generic provisions, and whether the agreement was submitted for antitrust review under the Federal Trade Commission reporting framework.[6]

How does lofexidine compare with clonidine and other opioid-withdrawal products?

Factor	Lofexidine	Clonidine
FDA status for opioid withdrawal	Specifically approved for mitigation of opioid withdrawal symptoms	Often used off-label
Pharmacology	Alpha-2 adrenergic agonist	Alpha-2 adrenergic agonist
Dosing burden	Multiple daily doses	Multiple daily doses
Cardiovascular concerns	Hypotension, bradycardia, QT prolongation	Hypotension, sedation, bradycardia
Generic competition	Present or developing through ANDA products	Broad generic availability
Formulation opportunity	Low-dose uniformity and adherence packaging	Commodity generic formulations
Commercial differentiation	Label specificity and withdrawal-focused positioning	Low price and clinical familiarity

Lofexidine’s commercial value is constrained by generic substitution and competition from inexpensive clonidine. Excipient innovation can improve cost, manufacturability, and supply reliability, but it is unlikely to create a large premium without a meaningful dosage-form or adherence benefit.

What revenue exposure exists for branded and generic lofexidine?

Revenue exposure is driven by four variables:

1. Generic launch timing.
2. Net price after rebates and payer restrictions.
3. Opioid-withdrawal treatment volume.
4. The share of patients receiving lofexidine rather than clonidine or supportive care.

The reference product faces price compression after generic entry. Generic manufacturers can still achieve attractive returns if development costs are low, manufacturing is outsourced efficiently, and the product has limited early competition.

For excipient companies, the addressable opportunity is smaller per product but scalable across portfolios. A successful low-dose tablet platform can be reused for other drugs requiring content-uniformity control, creating a stronger business case than a lofexidine-specific excipient sale.

Key Takeaways

• Lofexidine hydrochloride is a 0.18 mg immediate-release tablet, making content uniformity the central formulation challenge.
• The reference formulation uses conventional excipients, including lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate.[1]
• Direct compression is the most commercially attractive starting platform; dry granulation is a useful fallback for flow or segregation problems.
• The strongest excipient opportunities are co-processed filler-binders, superdisintegrants, low-lubrication systems, moisture-resistant coatings, and high-barrier packaging.
• Broad patents covering standard excipient combinations are likely to face significant validity and design-around pressure.
• Manufacturing-process and stability patents may provide stronger protection than generic composition claims.
• Generic entry, not biosimilar competition, is the main exclusivity risk.
• Lofexidine competes with low-cost clonidine, limiting the pricing premium available from formulation improvements.
• Adherence packaging and simplified treatment-duration packs offer more credible commercial differentiation than minor changes to tablet excipients.
• The commercial value of a lofexidine excipient platform increases when the same technology can be applied to other low-dose generic tablets.

FAQs

Can lofexidine hydrochloride be formulated as an orally disintegrating tablet?

Yes. An orally disintegrating formulation is technically feasible, but it would require evaluation of palatability, mechanical strength, moisture sensitivity, dissolution, and regulatory pathway. A conventional ANDA is simplest if the product remains pharmaceutically equivalent to the reference tablet.

Which excipient is most important for lofexidine content uniformity?

The filler-binder system is usually the most important starting point because it controls particle distribution, blend flow, and segregation. Colloidal silicon dioxide and process controls can support uniformity but do not replace appropriate particle-size matching and blending design.

Is magnesium stearate appropriate for lofexidine tablets?

Yes, magnesium stearate is a standard tablet lubricant. Its concentration and mixing time should be controlled because over-lubrication can reduce tablet wetting, slow disintegration, and alter dissolution.

Does lofexidine have biosimilar risk?

No. Lofexidine is a chemically synthesized small molecule. Competition proceeds through generic-drug pathways, primarily ANDAs, rather than through biosimilar applications.

Can a new lofexidine excipient formulation support a 505(b)(2) application?

Potentially, if the formulation creates a meaningful change in dosage form, pharmacokinetics, administration, or clinical use. A routine excipient substitution that maintains the reference product’s dosage form and performance is more likely to fit the ANDA pathway.

References

1. U.S. Food and Drug Administration. (2018). Lucemyra (lofexidine hydrochloride) tablets, prescribing information. NDA 209229.

2. U.S. Food and Drug Administration. (2024). Code of Federal Regulations, Title 21, Part 320: Bioavailability and bioequivalence requirements.

3. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2018). Approval package for NDA 209229: Lucemyra.

5. U.S. Food and Drug Administration. (2024). Approved Drug Products with Therapeutic Equivalence Evaluations, Orange Book.

6. Federal Trade Commission. (2024). Agreement filings under the Medicare Prescription Drug, Improvement, and Modernization Act.